Automated insulin delivery system link-up between Sequel Med Tech and Senseonics, extending to CGM (Continuous Glucose Monitoring) for one year.
In a significant development for diabetes management, Sequel's twiist Automated Insulin Delivery (AID) System is now officially compatible with Senseonics' Eversense 365 Continuous Glucose Monitoring (CGM) system. This integration marks the first AID system that works directly with the Eversense 365 sensor, enabling automated insulin delivery based on the sensor's glucose readings.
The Eversense 365 CGM offers implantable, long-term glucose monitoring for up to a full year of wear. Its new design is intended to seamlessly integrate with twiist. The twiist system uses advanced features such as sound waves to distinguish insulin occlusions from air bubbles, ensuring more precise insulin dosing.
Senseonics filed for CE mark approval for the Eversense 365, targeting a European launch in the second half of 2025, which coincides with the timeline of this integration gaining official compatibility. The integrated system is expected to be available in the third quarter of the current year.
Eversense 365 received FDA clearance in September 2024 as an integrated continuous glucose monitoring (iCGM) system for people with diabetes. Sequel CEO and Co-Founder Alan Lotvin expressed commitment to investing in innovations that empower people with diabetes.
The collaboration between Sequel Med Tech and Senseonics Holdings is expected to offer people with type 1 diabetes enhanced diabetes management tools. Both companies are united by a shared commitment to simplifying diabetes management and improving quality of life.
People living with type 1 diabetes who use twiist will now have the flexibility to select from two compatible CGM partners: Senseonics Eversense 365 and Abbott's FreeStyle Libre 3 Plus sensor. The expanded CGM compatibility between Eversense and twiist offers greater personalization, more choice, and the potential for improved outcomes for people living with diabetes.
Senseonics President and CEO Tim Goodnow stated the collaboration marks a significant step forward in transforming diabetes care. Improved glucose control, increased convenience, and greater flexibility are potential benefits of the integrated system.
This development is a significant advancement in combined CGM and automated insulin delivery therapy for diabetes management, representing a milestone in diabetes care technology.
Science has taken a step forward in diabetes management with Sequel's twiist Automated Insulin Delivery System now working seamlessly with Senseonics' Eversense 365 medical-conditions monitoring system, leading to health-and-wellness improvements for people with diabetes. The integrated system, set to be available in the third quarter of the current year, offers two compatible CGM partners, opening up more choices and potential for improved outcomes.
%20for%20one%20year.){kind=link}